September 7, 2022
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) became the top-selling drug in Japan for the eight consecutive month in August, according to a monthly snapshot report released by Encise. Opdivo hauled in sales of 14 billion yen on an NHI price...read more